INVESTORS

Publications

A Phase 1 Study of SRA737 Administered Orally in Patients with Advanced Cancer
American Society Of Clinical Oncology (ASCO) Annual Meeting – June 2017

Screening the druggable genome for synthetic lethal interactions with the CHK1 inhibitor PNT737 (SRA737)
American Association for Cancer Research (AACR) Annual Meeting – April 2017